Nian Jiayun, Sun Xu, Guo Jiao, Yan Chen, Wang Xiaomin, Yang Guowang, Yang Lin, Yu Mingwei, Zhang Ganlin
Oncology Department, Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Beijing, China School of Graduates, Beijing University of Chinese Medicine, Beijing, China.
Oncology Department, Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Beijing, China.
BMJ Open. 2016 May 26;6(5):e010787. doi: 10.1136/bmjopen-2015-010787.
Many cancer patients experience leucopoenia during chemotherapy. Granulocyte- colony-stimulating factor (G-CSF) is used to treat chemotherapy-induced leucopoenia (CIL) but has various limitations. Clinical trials have indicated that acupuncture may prevent bone marrow suppression and increase leucocyte counts after chemotherapy. The objective of this review is to assess the efficacy and safety of acupuncture for treating CIL.
This systematic review will electronically search the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Library, Medline, EMBASE, the China National Knowledge Infrastructure Database (CNKI), the Chinese Biomedical Literature Database (CBM), the Chinese Scientific Journal Database (VIP Database) and the Wanfang database from their inception to 1 January 2016. Other sources will also be searched including potential grey literature, conference proceedings and the reference lists of identified publications and existing systematic reviews. Two reviewers will independently search the databases, perform data extraction and assess the quality of studies. Data will be synthesised by either the fixed-effects or the random-effects model according to a heterogeneity test. White blood cell counts will be assessed as the primary outcome. Adverse effects, incidence of leucopoenia, quality of life and physical condition will be evaluated as secondary outcomes. RevMan V.5.3 will be employed for data analysis. The results will be expressed as risk ratios for dichotomous data and mean differences for continuous data.
The protocol does not need ethics approval because individuals cannot be identified. The review will be reported in a peer-reviewed publication or at a relevant conference.
CRD42015027594.
许多癌症患者在化疗期间会出现白细胞减少。粒细胞集落刺激因子(G-CSF)用于治疗化疗引起的白细胞减少(CIL),但有各种局限性。临床试验表明,针灸可能预防化疗后的骨髓抑制并增加白细胞计数。本综述的目的是评估针灸治疗CIL的疗效和安全性。
本系统评价将通过电子检索以下数据库:Cochrane对照试验中心注册库(CENTRAL)、Cochrane图书馆、医学期刊数据库(Medline)、荷兰医学文摘数据库(EMBASE)、中国知网数据库(CNKI)、中国生物医学文献数据库(CBM)、维普中文科技期刊数据库(VIP数据库)和万方数据库,检索时间从建库至2016年1月1日。还将检索其他来源,包括潜在的灰色文献、会议论文集以及已识别出版物和现有系统评价的参考文献列表。两名评价员将独立检索数据库、进行数据提取并评估研究质量。根据异质性检验,采用固定效应模型或随机效应模型对数据进行合并。白细胞计数将作为主要结局进行评估。不良反应、白细胞减少的发生率、生活质量和身体状况将作为次要结局进行评估。将使用RevMan V.5.3进行数据分析。结果将以二分类数据的风险比和连续数据的均值差表示。
由于无法识别个体,本方案无需伦理批准。本综述将在同行评审的出版物或相关会议上报告。
CRD42015027594。